Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy
In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the musc...
Gespeichert in:
Veröffentlicht in: | The Journal of clinical investigation 2007-12, Vol.117 (12), p.3952-3957 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 3957 |
---|---|
container_issue | 12 |
container_start_page | 3952 |
container_title | The Journal of clinical investigation |
container_volume | 117 |
creator | Wheeler, Thurman M Lueck, John D Swanson, Maurice S Dirksen, Robert T Thornton, Charles A |
description | In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM. |
doi_str_mv | 10.1172/jci33355 |
format | Article |
fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2075481</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A172599262</galeid><sourcerecordid>A172599262</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</originalsourceid><addsrcrecordid>eNqNkktr3DAUhb1oSdKk0F9QtCrtwqmefmwKwfQxJRBIH1sjS1e2giy5lifU_76aztBmIIsgoSt0v3sWRyfLXhF8SUhJ398pyxgT4ll2hjEleV2y6jR7EeMdxoRzwU-yU1JhnHZ9lv1qwjyDWmzwKBjUuCYnKE7OKut7BM6O1ssFIlKDC7PVkC7Se3BhksuwIuk1GtewBG8lsh6NYRshnRpc3AkeegrpNS5zmIb1IntupIvw8lDPsx-fPn5vvuTXN583zdV1rkRRiLwQmhOuuxKIqBgGKmnBuKGmK0qiDead7LoaV5yyQmNSsgJTXbFaEMWFYZKdZx_2utO2G0Er8MssXTvNdpTz2gZp2-OOt0Pbh_uW4lLwiiSBfC_QSwet9SYkTPXgIdHBg7Hp-SpZLuqaFjTxl4_waWkYrXp04N3RQGIW-L30chtju_l2-3T25ucx--YBO4B0yxCD2-4-OR6Db_egmkOMM5h_7hDc7sLUfm02f8OU0NcP3fwPHpLE_gD8HcV_</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</creator><creatorcontrib>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</creatorcontrib><description>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</description><identifier>ISSN: 0021-9738</identifier><identifier>DOI: 10.1172/jci33355</identifier><identifier>PMID: 18008009</identifier><language>eng</language><publisher>United States: American Society for Clinical Investigation</publisher><subject>Action Potentials - drug effects ; Action Potentials - genetics ; Alternative Splicing - drug effects ; Alternative Splicing - genetics ; Animals ; Channelopathies - drug therapy ; Channelopathies - genetics ; Channelopathies - metabolism ; Chloride channels ; Chloride Channels - biosynthesis ; Chloride Channels - genetics ; Exons - genetics ; Genetic aspects ; Genetic engineering ; Health aspects ; Methods ; Mice ; Myotonia Congenita - drug therapy ; Myotonia Congenita - genetics ; Myotonia Congenita - metabolism ; Myotonic dystrophy ; Myotonic Dystrophy - drug therapy ; Myotonic Dystrophy - genetics ; Myotonic Dystrophy - metabolism ; Oligodeoxyribonucleotides, Antisense - pharmacology ; Oligodeoxyribonucleotides, Antisense - therapeutic use ; Risk factors ; RNA Splice Sites - genetics ; Sarcolemma - genetics ; Sarcolemma - metabolism</subject><ispartof>The Journal of clinical investigation, 2007-12, Vol.117 (12), p.3952-3957</ispartof><rights>COPYRIGHT 2007 American Society for Clinical Investigation</rights><rights>Copyright © 2007, American Society for Clinical Investigation 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</citedby><cites>FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075481/pdf/$$EPDF$$P50$$Gpubmedcentral$$H</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC2075481/$$EHTML$$P50$$Gpubmedcentral$$H</linktohtml><link.rule.ids>230,314,727,780,784,885,27923,27924,53790,53792</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18008009$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Wheeler, Thurman M</creatorcontrib><creatorcontrib>Lueck, John D</creatorcontrib><creatorcontrib>Swanson, Maurice S</creatorcontrib><creatorcontrib>Dirksen, Robert T</creatorcontrib><creatorcontrib>Thornton, Charles A</creatorcontrib><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><title>The Journal of clinical investigation</title><addtitle>J Clin Invest</addtitle><description>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</description><subject>Action Potentials - drug effects</subject><subject>Action Potentials - genetics</subject><subject>Alternative Splicing - drug effects</subject><subject>Alternative Splicing - genetics</subject><subject>Animals</subject><subject>Channelopathies - drug therapy</subject><subject>Channelopathies - genetics</subject><subject>Channelopathies - metabolism</subject><subject>Chloride channels</subject><subject>Chloride Channels - biosynthesis</subject><subject>Chloride Channels - genetics</subject><subject>Exons - genetics</subject><subject>Genetic aspects</subject><subject>Genetic engineering</subject><subject>Health aspects</subject><subject>Methods</subject><subject>Mice</subject><subject>Myotonia Congenita - drug therapy</subject><subject>Myotonia Congenita - genetics</subject><subject>Myotonia Congenita - metabolism</subject><subject>Myotonic dystrophy</subject><subject>Myotonic Dystrophy - drug therapy</subject><subject>Myotonic Dystrophy - genetics</subject><subject>Myotonic Dystrophy - metabolism</subject><subject>Oligodeoxyribonucleotides, Antisense - pharmacology</subject><subject>Oligodeoxyribonucleotides, Antisense - therapeutic use</subject><subject>Risk factors</subject><subject>RNA Splice Sites - genetics</subject><subject>Sarcolemma - genetics</subject><subject>Sarcolemma - metabolism</subject><issn>0021-9738</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkktr3DAUhb1oSdKk0F9QtCrtwqmefmwKwfQxJRBIH1sjS1e2giy5lifU_76aztBmIIsgoSt0v3sWRyfLXhF8SUhJ398pyxgT4ll2hjEleV2y6jR7EeMdxoRzwU-yU1JhnHZ9lv1qwjyDWmzwKBjUuCYnKE7OKut7BM6O1ssFIlKDC7PVkC7Se3BhksuwIuk1GtewBG8lsh6NYRshnRpc3AkeegrpNS5zmIb1IntupIvw8lDPsx-fPn5vvuTXN583zdV1rkRRiLwQmhOuuxKIqBgGKmnBuKGmK0qiDead7LoaV5yyQmNSsgJTXbFaEMWFYZKdZx_2utO2G0Er8MssXTvNdpTz2gZp2-OOt0Pbh_uW4lLwiiSBfC_QSwet9SYkTPXgIdHBg7Hp-SpZLuqaFjTxl4_waWkYrXp04N3RQGIW-L30chtju_l2-3T25ucx--YBO4B0yxCD2-4-OR6Db_egmkOMM5h_7hDc7sLUfm02f8OU0NcP3fwPHpLE_gD8HcV_</recordid><startdate>200712</startdate><enddate>200712</enddate><creator>Wheeler, Thurman M</creator><creator>Lueck, John D</creator><creator>Swanson, Maurice S</creator><creator>Dirksen, Robert T</creator><creator>Thornton, Charles A</creator><general>American Society for Clinical Investigation</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISR</scope><scope>5PM</scope></search><sort><creationdate>200712</creationdate><title>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</title><author>Wheeler, Thurman M ; Lueck, John D ; Swanson, Maurice S ; Dirksen, Robert T ; Thornton, Charles A</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5665-65d414db7e15830e2a2634f2fb671df04babb9084236d0173602d83951c45f3a3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Action Potentials - drug effects</topic><topic>Action Potentials - genetics</topic><topic>Alternative Splicing - drug effects</topic><topic>Alternative Splicing - genetics</topic><topic>Animals</topic><topic>Channelopathies - drug therapy</topic><topic>Channelopathies - genetics</topic><topic>Channelopathies - metabolism</topic><topic>Chloride channels</topic><topic>Chloride Channels - biosynthesis</topic><topic>Chloride Channels - genetics</topic><topic>Exons - genetics</topic><topic>Genetic aspects</topic><topic>Genetic engineering</topic><topic>Health aspects</topic><topic>Methods</topic><topic>Mice</topic><topic>Myotonia Congenita - drug therapy</topic><topic>Myotonia Congenita - genetics</topic><topic>Myotonia Congenita - metabolism</topic><topic>Myotonic dystrophy</topic><topic>Myotonic Dystrophy - drug therapy</topic><topic>Myotonic Dystrophy - genetics</topic><topic>Myotonic Dystrophy - metabolism</topic><topic>Oligodeoxyribonucleotides, Antisense - pharmacology</topic><topic>Oligodeoxyribonucleotides, Antisense - therapeutic use</topic><topic>Risk factors</topic><topic>RNA Splice Sites - genetics</topic><topic>Sarcolemma - genetics</topic><topic>Sarcolemma - metabolism</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Wheeler, Thurman M</creatorcontrib><creatorcontrib>Lueck, John D</creatorcontrib><creatorcontrib>Swanson, Maurice S</creatorcontrib><creatorcontrib>Dirksen, Robert T</creatorcontrib><creatorcontrib>Thornton, Charles A</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Science</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>The Journal of clinical investigation</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Wheeler, Thurman M</au><au>Lueck, John D</au><au>Swanson, Maurice S</au><au>Dirksen, Robert T</au><au>Thornton, Charles A</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy</atitle><jtitle>The Journal of clinical investigation</jtitle><addtitle>J Clin Invest</addtitle><date>2007-12</date><risdate>2007</risdate><volume>117</volume><issue>12</issue><spage>3952</spage><epage>3957</epage><pages>3952-3957</pages><issn>0021-9738</issn><abstract>In myotonic dystrophy (dystrophia myotonica [DM]), an increase in the excitability of skeletal muscle leads to repetitive action potentials, stiffness, and delayed relaxation. This constellation of features, collectively known as myotonia, is associated with abnormal alternative splicing of the muscle-specific chloride channel (ClC-1) and reduced conductance of chloride ions in the sarcolemma. However, the mechanistic basis of the chloride channelopathy and its relationship to the development of myotonia are uncertain. Here we show that a morpholino antisense oligonucleotide (AON) targeting the 3' splice site of ClC-1 exon 7a reversed the defect of ClC-1 alternative splicing in 2 mouse models of DM. By repressing the inclusion of this exon, the AON restored the full-length reading frame in ClC-1 mRNA, upregulated the level of ClC-1 mRNA, increased the expression of ClC-1 protein in the surface membrane, normalized muscle ClC-1 current density and deactivation kinetics, and eliminated myotonic discharges. These observations indicate that the myotonia and chloride channelopathy observed in DM both result from abnormal alternative splicing of ClC-1 and that antisense-induced exon skipping offers a powerful method for correcting alternative splicing defects in DM.</abstract><cop>United States</cop><pub>American Society for Clinical Investigation</pub><pmid>18008009</pmid><doi>10.1172/jci33355</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0021-9738 |
ispartof | The Journal of clinical investigation, 2007-12, Vol.117 (12), p.3952-3957 |
issn | 0021-9738 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2075481 |
source | MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
subjects | Action Potentials - drug effects Action Potentials - genetics Alternative Splicing - drug effects Alternative Splicing - genetics Animals Channelopathies - drug therapy Channelopathies - genetics Channelopathies - metabolism Chloride channels Chloride Channels - biosynthesis Chloride Channels - genetics Exons - genetics Genetic aspects Genetic engineering Health aspects Methods Mice Myotonia Congenita - drug therapy Myotonia Congenita - genetics Myotonia Congenita - metabolism Myotonic dystrophy Myotonic Dystrophy - drug therapy Myotonic Dystrophy - genetics Myotonic Dystrophy - metabolism Oligodeoxyribonucleotides, Antisense - pharmacology Oligodeoxyribonucleotides, Antisense - therapeutic use Risk factors RNA Splice Sites - genetics Sarcolemma - genetics Sarcolemma - metabolism |
title | Correction of ClC-1 splicing eliminates chloride channelopathy and myotonia in mouse models of myotonic dystrophy |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-11T03%3A56%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correction%20of%20ClC-1%20splicing%20eliminates%20chloride%20channelopathy%20and%20myotonia%20in%20mouse%20models%20of%20myotonic%20dystrophy&rft.jtitle=The%20Journal%20of%20clinical%20investigation&rft.au=Wheeler,%20Thurman%20M&rft.date=2007-12&rft.volume=117&rft.issue=12&rft.spage=3952&rft.epage=3957&rft.pages=3952-3957&rft.issn=0021-9738&rft_id=info:doi/10.1172/jci33355&rft_dat=%3Cgale_pubme%3EA172599262%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/18008009&rft_galeid=A172599262&rfr_iscdi=true |